- Home
- ZENV vs ACHV Comparison
ZENV vs ACHV Comparison
Compare ZENV & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- ACHV
- Stock Information
- Founded
- ZENV 2005
- ACHV N/A
- Country
- ZENV Brazil
- ACHV United States
- Employees
- ZENV N/A
- ACHV N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ZENV Technology
- ACHV Health Care
- Exchange
- ZENV Nasdaq
- ACHV Nasdaq
- Market Cap
- ZENV 79.2M
- ACHV 72.5M
- IPO Year
- ZENV 2021
- ACHV N/A
- Fundamental
- Price
- ZENV $1.51
- ACHV $2.11
- Analyst Decision
- ZENV
- ACHV Strong Buy
- Analyst Count
- ZENV 0
- ACHV 3
- Target Price
- ZENV N/A
- ACHV $14.33
- AVG Volume (30 Days)
- ZENV 74.2K
- ACHV 1.1M
- Earning Date
- ZENV 07-02-2025
- ACHV 08-12-2025
- Dividend Yield
- ZENV N/A
- ACHV N/A
- EPS Growth
- ZENV N/A
- ACHV N/A
- EPS
- ZENV N/A
- ACHV N/A
- Revenue
- ZENV $155,164,999.00
- ACHV N/A
- Revenue This Year
- ZENV $8.58
- ACHV N/A
- Revenue Next Year
- ZENV $8.83
- ACHV N/A
- P/E Ratio
- ZENV N/A
- ACHV N/A
- Revenue Growth
- ZENV 18.83
- ACHV N/A
- 52 Week Low
- ZENV $1.02
- ACHV $1.84
- 52 Week High
- ZENV $3.03
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- ZENV 51.14
- ACHV 53.11
- Support Level
- ZENV $1.43
- ACHV $3.44
- Resistance Level
- ZENV $1.90
- ACHV $3.90
- Average True Range (ATR)
- ZENV 0.16
- ACHV 0.28
- MACD
- ZENV 0.01
- ACHV -0.01
- Stochastic Oscillator
- ZENV 34.26
- ACHV 56.99
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.